Sinha Uma, Sinharay Keshab, Sengupta Nilanjan, Mukhopadhyay Prasanta
Department of Medicine, Nilratan Sircar Medical College, Kolkata, India.
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 3):S637-43. doi: 10.4103/2230-8210.105583.
Leptin therapy in human recombinant form has recently been used in HIV-associated lipodystrophy syndrome on experimental basis in some small short-term clinical trials. It has shown its beneficial effects only in hypoleptinemic HIV-infected patients by causing definite improvement in their insulin sensitivity, glucose tolerance, lipid status, and truncal obesity. Leptin prevents lipotoxicity and activates insulin signaling pathways through several postulated mechanisms. Central leptin insufficiency with peripheral hyperleptinemia has come out to be a significant contributor to the development of obesity and metabolic syndrome. In this article, we will review the basis of leptin therapy in HIV patients, with its promises. However, further larger clinical trials are needed to prove its long-term efficacy in the control of metabolic complications related to HIV therapy.
人重组形式的瘦素疗法最近已在一些小型短期临床试验的实验基础上用于治疗与艾滋病相关的脂肪代谢障碍综合征。仅在低瘦素血症的艾滋病感染患者中,它通过明确改善其胰岛素敏感性、葡萄糖耐量、脂质状况和腹部肥胖显示出有益效果。瘦素通过几种假定的机制预防脂毒性并激活胰岛素信号通路。中枢性瘦素不足伴外周血瘦素血症已被证明是肥胖和代谢综合征发展的重要因素。在本文中,我们将回顾瘦素疗法在艾滋病患者中的依据及其前景。然而,需要进一步的大型临床试验来证明其在控制与艾滋病治疗相关的代谢并发症方面的长期疗效。